Brief, factual summary of the article in Slovak: The PRESERVE-003 study investigated the efficacy of the new drug gotistobart compared to docetaxel in the treatment of patients with metastatic squamous non-small cell lung cancer who were resistant to immunochemotherapy and did not have effective genomic alterations. It was an independent stage 1 randomized phase 3 clinical trial. Patients were treated with either gotistobart or docetaxel. The study investigated the efficacy and safety of these two treatment approaches in a given group of patients.